General Clinical Research Ctr:Pharmacogenetics Core Supp

描述(由申请人提供)： 这项申请是为了在印第安纳大学医学院为GCRC建立一个药物遗传学核心实验室。拟议的核心将通过最近招募NIGMS资助的药物遗传学研究网络而得到促进，该网络为印第安纳大学医学院的药物遗传学提供了重点，该学院在遗传学领域具有历史上的实力。此外，临床药理学分部还开设了一门药物遗传学课程，该课程将与印第安纳大学临床研究的K-30培训计划相结合，并于2003年秋季开课。这将向学员介绍通过药理学部门提供的更广泛的药物遗传学课程，作为T-32资助的临床药理学课程的一部分。拟议的核心将支持和促进目前在这一新兴领域开展的研究；招募对基因组研究感兴趣的年轻研究人员；并作为药物遗传学的培训计划。目前，25项GCRC协议支持由9名研究人员资助的NIH资助的490万美元研究，其中包含药物遗传学部分。建立GCRC药物遗传学核心有可能支持印第安纳大学医学中心3个部门和5个部门的50个GCRC方案。 David Flockhart，医学博士，临床药理学分部博士，2000年被印第安纳大学录用，1998年在乔治敦大学医学中心GCRC内建立了一个药物遗传学核心实验室。这是GCRC计划内的第一个这样的核心。乔治敦大学的药物遗传学研究小组，包括8名教职员工和所有核心实验室人员，也搬到了印第安纳大学。该小组得到了新的设备和工作人员的补充，并得到了临床药理学司内翻新的空间。印第安纳大学代表着一个肥沃的药物遗传学研究的学术环境，是该州唯一的学术医学中心，在遗传学和临床药理学方面都有很强的历史。印第安纳大学医学中心已经建立了涉及大量患者群体的主要遗传学计划，这些计划有助于涉及许多学科的药物遗传学研究。此外，癌症、精神病学和儿科的药物遗传学最近有所扩大，这反映在癌症中心、精神病学系和儿科对这一核心应用的支持。 总之，拟议的核心实验室将既是GCRC方案的关键服务设施，也是吸引年轻研究人员参与临床研究的强有力的培训计划。

DESCRIPTION (provided by applicant): This application is to establish a Pharmacogenetics Core Laboratory for the GCRC at the Indiana University School of Medicine. The proposed core will be facilitated by the recent recruitment of a NIGMS funded Pharmacogenetics Research Network which provides a focus for pharmacogenetics at Indiana University Medical School that has that has historical strength in the field of genetics. In addition, the Division of Clinical Pharmacology has a pharmacogenetics course that will be integrated with the K-30 training program in clinical research at Indiana University and offered in the fall of 2003. This will introduce trainees to the more extensive program in pharmacogenetics available through the Division of Pharmacology as part of the T-32 funded program in Clinical Pharmacology. The proposed core will support and catalyze research currently being carried out in this emerging field; recruit young investigators attracted to genomic research; and serve as a training program in pharmacogenetics. Currently, 25 GCRC protocols supporting $4.9 million of NIH-funded research by 9 investigators have a pharmacogenetics component. The establishment of a GCRC pharmacogenetics core has the potential to support 50 GCRC protocols in 3 Departments and 5 Divisions of the Indiana University Medical Center. David Flockhart, MD, PhD, in the Division of Clinical Pharmacology, was recruited to Indiana University in 2000, having established a Pharmacogenetics Core Laboratory within the GCRC at Georgetown University Medical Center in 1998. This was the first such core within the GCRC program. The pharmacogenetics research group at Georgetown, including 8 faculty and staff and all core laboratory personnel, also moved to Indiana University. The group has been supplemented by new equipment and staff and by renovated space within the Division of Clinical Pharmacology. Indiana University represents a fertile academic environment for pharmacogenetic studies, being the only academic medical center in the state, and having a strong history in both genetics and clinical pharmacology. Indiana University Medical Center has established major genetic programs involving large patient populations which lend themselves to pharmacogenetic research embracing many disciplines. In addition, pharmacogenetics in cancer, psychiatry, and pediatrics have recently expanded, which is reflected by the support of the Cancer Center, Department of Psychiatry, and the Department of Pediatrics for this core application. In summary, the proposed core laboratory will function both as a key service facility to GCRC protocols and as a strong training program to attract young investigators to clinical research.